Haema Logi X Announces Appointment of Damian Clarke Bruce As Managing Director and CEO

Nov 14, 2023•almost 2 years ago

Position

Managing Director

Company

HaemaLogiX

Damian Clarke-Bruce

SydneyTherapeuticsBiotechnologyHealth CareManufacturing

Description

HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.

Company Information

Company

HaemaLogiX

Location

Sydney, New South Wales, Australia

About

HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX is embarking on a program of several inter-related research and clincial development projects that will validate the antigen targets and products. We have a unique opportunity to develop effective treatments that improve the quality of life of patients suffering from blood cancers and autoimmune diseases.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months